Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low at $22.51

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as $22.51 and last traded at $22.53, with a volume of 1097601 shares traded. The stock had previously closed at $24.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NTLA shares. Canaccord Genuity Group upped their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Friday, February 23rd. Wolfe Research started coverage on shares of Intellia Therapeutics in a research report on Thursday, February 15th. They issued a "peer perform" rating for the company. Wedbush reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research report on Thursday, February 15th. Finally, The Goldman Sachs Group cut shares of Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Intellia Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $67.00.

Intellia Therapeutics Price Performance

The stock's 50-day moving average is $27.69 and its 200 day moving average is $28.14. The company has a market cap of $2.20 billion, a PE ratio of -4.24 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the prior year, the business posted ($1.40) EPS. On average, analysts expect that Intellia Therapeutics, Inc. will post -5.58 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Los Angeles Capital Management LLC increased its stake in shares of Intellia Therapeutics by 49.2% in the first quarter. Los Angeles Capital Management LLC now owns 17,449 shares of the company's stock worth $480,000 after acquiring an additional 5,754 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Intellia Therapeutics by 209.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,561 shares of the company's stock worth $322,000 after acquiring an additional 7,151 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $9,086,000. Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company's stock worth $254,514,000 after acquiring an additional 155,579 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Intellia Therapeutics by 3.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 824,527 shares of the company's stock worth $25,140,000 after acquiring an additional 28,264 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.